News Lotus Pharmaceutical Co., Ltd.

Equities

1795

TW0001795003

End-of-day quote Taiwan S.E. Other stock markets 2024-09-11			5-day change	1st Jan Change
270.50 ^TWD	-2.70%		-1.28%	-0.55%

09-06	Lotus Pharmaceutical Board to Acquire Product Rights of Vietnamese Firm	MT
09-05	Lotus Pharmaceutical Co., Ltd. agreed to acquire Intellectual Property rights of Alpha Choay from Sanofi Vietnam Shareholding Company for $50 million.	CI

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Lotus Pharmaceutical Board to Acquire Product Rights of Vietnamese Firm	09-06	MT
Lotus Pharmaceutical Co., Ltd. agreed to acquire Intellectual Property rights of Alpha Choay from Sanofi Vietnam Shareholding Company for $50 million.	09-04	CI
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Wanida Boonpiraks as Representative of the Institutional Director	08-21	CI
Lotus Pharmaceutical Co., Ltd. Announces the Resignation of Phannalin Mahawongtikul as Director	08-16	CI
Lotus Reported Unaudited July Revenues of NT$2,722 million, second-highest monthly revenue in the company's history	08-12	AQ
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-07	CI
Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. completed the acquisition of Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V.	07-31	CI
Lotus Pharmaceutical Honored 2024 Taiwan BIO Awards- Outstanding Company of the Year, Showcasing Excellence in Operational Performance, Development Strategy, and Technological Innovation	07-29	AQ
Lotus Pharmaceutical Co., Ltd. Announces Cash Dividend, Payable on August 30, 2024	07-18	CI
Lotus Pharmaceuticals Secures Three HR Asia Awards for 2024	07-08	AQ
Nrx Pharmaceuticals, Inc. Receives A Notice of Termination of Exclusive, Global ? Development, Supply, Marketing & License Agreement by and Between Alvogen, Inc., Alvogen Pharma Us, Inc. and Lotus Pharmaceutical Co. Ltd	06-27	CI
Lotus Pharmaceutical Co., Ltd. Announces Audit and Remuneration Committee Changes	06-13	CI
Lotus Pharmaceutical Co., Ltd. Announces Board Changes	06-13	CI
Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. agreed to acquire Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion.	06-05	CI
Transcript : Lotus Pharmaceutical Co., Ltd., Q1 2024 Earnings Call, May 16, 2024	05-16
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director	03-26	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-13	CI
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024	01-31	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lotus Pharmaceutical Co., Ltd.

Equities

1795

TW0001795003

Filters